SCHEMBL55106

SCHEMBL55106

O=S(=O)(OCC(F)(F)F)C(Cl)(Cl)Cl

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7899371 0.81 CA1 (0.33) CA1CA2CA9
SCHEMBL26912 0.79 CA2 (0.56) CA1CA2CA9HTT
SCHEMBL8927969 0.78 CA1 (0.31) CA1CA2CA9
SCHEMBL14600039 0.76 CA1 (0.33) CA1CA2CA9
SCHEMBL11917853 0.76 CA1 (0.30) CA1CA2CA9
SCHEMBL775983 0.75 CA1 (0.65) CA1CA2CA9HTT
SCHEMBL25850724 0.75 CA1 (0.52) CA1CA2CA9HTT
SCHEMBL777502 0.75 CA1 (0.52) CA1CA2CA9HTT
SCHEMBL972507 0.75 CA1 (0.52) CA1CA2CA9HTT
SCHEMBL9321989 0.74 CA1 (0.56) CA1CA2CA9HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 413 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4837364-A REACTION OF HALOBENZENE WITH TRIFLUOROETHANOL RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1989-06-06 US claimed
EP-0197869-B1 PROCESS FOR THE PREPARATION OF PENTAFLUOROETHOXY- AND PENTAFLUOROETHYL THIOBENZENE DERIVATIVES RHONE-POULENC CHIMIE (FR) 1989-05-31 EP claimed
EP-4076459-B1 PRMT5 INHIBITORS MERCK SHARP & DOHME LLC (US) 2026-04-29 EP disclosed
US-12595248-B2 PRMT5 inhibitors MERCK SHARP & DOHME LLC (US) 2026-04-07 US disclosed
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2025-03-27 US disclosed
US-12122765-B2 Methods and intermediates for preparing therapeutic compounds GILEAD SCIENCES, INC. (US) 2024-10-22 US disclosed
US-12064429-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use ADVERIO PHARMA GMBH (DE) 2024-08-20 US disclosed
EP-4403221-A2 MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS Gilead Sciences, Inc. (US) 2024-07-24 EP disclosed
EP-2487161-B2 Modulators of pharmacokinetic properties of therapeutics GILEAD SCIENCES INC (US) 2024-06-05 EP disclosed
US-20240101533-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2024-03-28 US disclosed
CN-114585628-B Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2024-03-26 CN disclosed
EP-0023422-A2 Herbicidal sulfonamides, preparation and use thereof, and compositions containing them E.I. DU PONT DE NEMOURS AND COMPANY (US) 1981-02-04 EP disclosed
US-4190666-A ANTIARTHRITIC, ANALGESIC E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-02-26 US disclosed
US-4182769-A ANALGESIC, ANTIARTHRITIC E. I. DU PONT DE NEMOURS AND COMPANY (US) 1980-01-08 US disclosed
US-4169146-A Novel morpholine derivatives and treating depression therewith SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1979-09-25 US disclosed
US-4159338-A ANTIARTHRITIC, ANALGESIC E. I. DU PONT DE NEMOURS AND COMPANY (US) 1979-06-26 US disclosed
US-4086236-A ANTIBACTERIAL E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-04-25 US disclosed
US-4085210-A Novel morpholine derivatives and the treatment of mental depression SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1978-04-18 US disclosed
US-4036962-A BACTERICIDES E. I. DU PONT DE NEMOURS AND CO. (US) 1977-07-19 US disclosed
US-4017621-A 2-Morpholinyl tricyclic dibenzazepine compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12122765-B2 Methods and intermediates for preparing therapeutic compounds CYP11A1, CYP11B1, CYP11B2 CA1 195/4885CA2 912/4885CA9 431/4885
US-12064429-B2 Substituted 5-fluoro-1H-pyrazolopyridines and their use PFKP, PON1, FABP3 CA1 4855/4885CA2 3900/4885CA9 4760/4885
US-12595248-B2 PRMT5 inhibitors PRMT5, PRMT1, PRMT6 CA1 3166/4885CA2 2138/4885CA9 3898/4885
US-20240101533-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 CA1 195/4885CA2 912/4885CA9 431/4885
US-20250100999-A1 METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS CYP11A1, CYP11B1, CYP11B2 CA1 195/4885CA2 912/4885CA9 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.